Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Mol Genet Genomic Med. 2024 Aug;12(8):e2449. doi: 10.1002/mgg3.2449.
The highest mortality and morbidity worldwide is associated with atherosclerotic cardiovascular disease (ASCVD), which has in background both environmental and genetic risk factors. Apolipoprotein L1 (APOL1) variability influences the risk of ASCVD in Africans, but little is known about the APOL1 and ASCVD in other ethnic groups.
To investigate the role of APOL1 and ASCVD, we have genotyped four (rs13056427, rs136147, rs10854688 and rs9610473) APOL1 polymorphisms in a group of 1541 male patients with acute coronary syndrome (ACS) and 1338 male controls.
Individual APOL1 polymorphisms were not associated with traditional CVD risk factors such as smoking, hypertension or diabetes prevalence, with BMI values or plasma lipid levels. Neither individual polymorphisms nor haplotypes were associated with an increased risk of ACS nor did they predict total or cardiovascular mortality over the 10.2 ± 3.9 years of follow-up.
We conclude that APOL1 genetic variability has no major effect on risk of ACS in Caucasians.
全球范围内，死亡率和发病率最高的疾病与动脉粥样硬化性心血管疾病（ASCVD）有关，其发生既与环境危险因素有关，也与遗传危险因素有关。载脂蛋白 L1（APOL1）的变异性会影响非洲人患 ASCVD 的风险，但人们对其他种族的 APOL1 和 ASCVD 知之甚少。
为了研究 APOL1 和 ASCVD 的作用，我们对 1541 名急性冠状动脉综合征（ACS）男性患者和 1338 名男性对照者的 4 个（rs13056427、rs136147、rs10854688 和 rs9610473）APOL1 多态性进行了基因分型。
单个 APOL1 多态性与传统 CVD 危险因素（如吸烟、高血压或糖尿病患病率、BMI 值或血浆脂质水平）无关。个体多态性或单倍型均与 ACS 风险增加无关，在 10.2±3.9 年的随访期间，也未预测总死亡率或心血管死亡率。
我们得出结论，APOL1 遗传变异对白人 ACS 风险没有重大影响。
